Stock Events

Stock Events

CHMMD 

$0.100000
4
+$0.00+0% Friday 13:30

Statistics

Day High
-
Day Low
-
52W High
0.1
52W Low
0.1
Volume
-
Avg. Volume
0
Mkt Cap
410.88M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

31AugExpected
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Next
-0.16
-0.11
-0.05
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-258.5%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
2.61MRevenue
-6.75MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is involved in gene editing and CAR T-cell therapies, a direct competitor in gene-based cancer treatments.
Allogene Therapeutics
ALLO
Mkt Cap697.89M
Allogene Therapeutics focuses on allogeneic CAR T therapies for cancers, directly competing with Chimeric's technologies.
Precigen
PGEN
Mkt Cap2.49B
Precigen operates in the synthetic biology field developing CAR T therapies, competing in the same innovative cancer treatment sector.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, through its acquisition of Kite Pharma, has become a leader in CAR T-cell therapies, directly competing in the oncology segment.
Novartis
NVS
Mkt Cap292.35B
Novartis is a major player in the healthcare sector with successful commercial CAR T-cell therapies, competing on a global scale.

About

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treatment of acute myeloid leukaemia/colorectal cancer, acute myeloid cancer, blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.
Show more...
CEO
Rebecca McQualter
Employees
5
Country
Australia
ISIN
AU0000460396

Listings

AU
AU
CHM.AU
OTC Link
US
CHMMF

0 Comments

Share your thoughts

FAQ

What is CHMMD stock price today?▼
The current price of CHMMD is $0.10 USD — it has increased by +0% in the past 24 hours. Watch CHMMD stock price performance more closely on the chart.
What is CHMMD stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTCM exchange CHMMD stocks are traded under the ticker CHMMD.
What is CHMMD market cap?▼
Today CHMMD has the market capitalization of 410.88M
What is CHMMD revenue for the last year?▼
CHMMD revenue for the last year amounts to 2.61M USD.
What is CHMMD net income for the last year?▼
CHMMD net income for the last year is -6.75M USD.
How many employees does CHMMD have?▼
As of September 04, 2026, the company has 5 employees.
In which sector is CHMMD located?▼
CHMMD operates in the Health & Wellness sector.
When did CHMMD complete a stock split?▼
The last stock split for CHMMD was on April 22, 2026 with a ratio of 1:100.
Where is CHMMD headquartered?▼
CHMMD is headquartered in Carlton, Australia.